Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenatoprazole
- Development stage
- Phase 1
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenatoprazole is a proton pump inhibitor (PPI) drug candidate developed by Mitsubishi Tanabe Pharma. It was designed to treat conditions like reflux oesophagitis and peptic ulcers. Tenatoprazole has an imidazopyridine ring instead of the benzimidazole moiety found in other PPIs, giving it a longer half-life compared to other drugs in its class. It works by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, thereby reducing stomach acid secretion.
- Other names
- benatoprazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on tenatoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenatoprazole.